RESUMEN
There is a paucity of information regarding the factors that affect nonrelapse mortality (NRM) and overall survival among children that develop chronic graft-versus-host disease (cGVHD). We performed multivariate analyses using data from the Center for International Blood and Marrow Transplant Research to identify risk factors for NRM and survival in 1117 pediatric subjects with leukemia or myelodysplastic syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between 1995 and 2004. We identified 4 variables associated with higher NRM: HLA partially matched or mismatched URD, peripheral blood cell graft, Karnofsky/Lansky score < 80 at cGVHD diagnosis, and platelets < 100 × 10(9)/L at cGVHD diagnosis. Factors associated with significantly worse survival were: age > 10 years, transplantation from HLA partially matched or mismatched URD, advanced disease at transplantation, Karnofsky/Lansky < 80; and platelets < 100 × 10(9)/L. Cumulative incidence of discontinuation of systemic immune suppression at 1, 3, and 5 years after diagnosis of cGVHD were 22% (20%-25%), 34% (31%-37%), and 37% (34%-40%), respectively. This is the largest study elucidating variables affecting outcome after diagnosis of cGVHD in pediatric allograft recipients. These variables may be useful for risk stratification, development of future clinical trials, and family counseling in children with cGVHD.
Asunto(s)
Sangre Fetal/trasplante , Enfermedad Injerto contra Huésped/epidemiología , Leucemia/cirugía , Síndromes Mielodisplásicos/cirugía , Adolescente , Adulto , Niño , Preescolar , Enfermedad Crónica , Femenino , Enfermedad Injerto contra Huésped/mortalidad , Humanos , Lactante , Recién Nacido , Masculino , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Adulto JovenRESUMEN
Positive pregnancy test results occurred in a nongravid, premenopausal woman while she was receiving chemotherapy for multiple myeloma. We tested 2 hypotheses to account for this finding: (1) Heterophil antibodies caused positive interference in the immunoassays. (2) Genuine human chorionic gonadotropin (hCG) originated from a nonsyncytiotrophoblastic source. Paraprotein was eliminated as a source of positive interference because 3 different instruments with unique capture and signal antibodies gave similar results (83, 90, and 97 mIU/mL [83, 90, and 97 IU/L]). Human antimouse antibodies (HAMAs) were unlikely to cause positive interference because immunoreactivity was maintained after serum was treated to neutralize heterophil antibodies. Immunoassays performed after gel filtration of serum indicated that immunoreactivity was due to genuine hCG. The high-molecular-weight fraction (heterophil antibody) had 6 mIU/mL (6 IU/L) of hCG. The low-molecular-weight fraction (hCG) had 86 mIU/mL (86 IU/L) of hCG. Immunohistochemical stains revealed that myeloma cells expressed immunoreactive hCG. Hence, multiple myeloma caused positive pregnancy test results in a nongravid woman.
Asunto(s)
Gonadotropina Coriónica Humana de Subunidad beta/biosíntesis , Mieloma Múltiple/metabolismo , Pruebas de Embarazo , Premenopausia , Adulto , Médula Ósea/metabolismo , Médula Ósea/patología , Gonadotropina Coriónica Humana de Subunidad beta/sangre , Reacciones Falso Positivas , Femenino , Humanos , Inmunohistoquímica , Células Plasmáticas/metabolismo , Células Plasmáticas/patología , EmbarazoRESUMEN
BACKGROUND AND OBJECTIVES: The homing of stem cells to the bone marrow microenvironment following transplantation is a specific movement eventually leading to the stem cells lodging in specialized niches of hematopoiesis. The present study was designed to develop an ex vivo expansion system capable of preserving the homing potential of hematopoietic stem/progenitor cells (HSPC). DESIGN AND METHODS: Umbilical cord blood (UCB) CD34+ cells were expanded in QBSF-60 serum-free medium with a simple early-acting combination of cytokines and were re-selected from the expanded products at different time points. The homing-related characteristics and expansion rate of CD34+ cells were simultaneously examined. RESULTS: It was observed that the number of HSPC increased significantly under our expansion protocol. The expression of CD49d, CD44, CD11a and CD49e on expanded CD34+ cells increased or remained at the same levels as those on freshly isolated CD34+ UCB cells, while the expression of CD54 on expanded CD34+ cells was lower during the second week of culture than at the start. The spontaneous and SDF-1-induced adhesion of CD34+ cells was increased during the first 10 days of culture, with the adhesion rates reaching peak levels (62.8 12.8% and 90.5 11.7% for spontaneous and induced adhesion, respectively) on day 10. Neither spontaneous nor SDF-1-induced migration had changed significantly by day 7. INTERPRETATION AND CONCLUSIONS: These data demonstrate that, although ex vivo expansion may alter cell properties, our one-week expansion protocol can preserve most of the homing-related characteristics and activities of UCB HSPC.
Asunto(s)
Sangre Fetal/citología , Células Madre Hematopoyéticas/fisiología , Antígenos CD34 , Adhesión Celular , Proliferación Celular , Separación Celular , Trasplante de Células Madre de Sangre del Cordón Umbilical , Medios de Cultivo , Fibronectinas/metabolismo , HumanosRESUMEN
An open labeled randomized trial comparing the efficacy and cost of empirically applied cefepime (C) as monotherapy versus combination therapy consisting of ticarcillin and clavulanate potassium and aztreonam (T/A) was performed in febrile neutropenic patients following high-dose chemotherapy (HDC) +/- radiation, with or without peripheral blood stem cell support. Over a 28-month period, 126 patients were screened and included in the study. Using afebrile status following 3 days of therapy as a primary endpoint, both regimens produced comparable clinical response rates (C = 55% vs. T/A = 61%). Also, the use of vancomycin for resistant gram-positive infections and alteration of gram-negative infection coverage was similar in both groups (C = 40% vs. T/A = 47% and C = 29% vs. T/A = 24%). Both treatment groups had similar needs for empirical antifungal therapy (C = 25% vs. T/A = 22%). There was a postrandomization difference between the two groups in that the "C" group had a significantly higher number of allogeneic transplants and non-stem-cell-supported patients, whereas the "T/A" group had a significantly greater number of autologous peripheral blood stem cell patients (p < 0.0001). Despite this difference, the C group had a significantly lower cost ratio than the T/A group (p = 0.016). In conclusion, we have shown that C treatment of febrile neutropenic patients following HDC results in similar efficacy and lower cost when compared to T/A, despite the inclusion of higher risk patients in the C group.
Asunto(s)
Antibacterianos/uso terapéutico , Aztreonam/uso terapéutico , Cefalosporinas/uso terapéutico , Ácido Clavulánico/uso terapéutico , Huésped Inmunocomprometido , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Infecciones Oportunistas/prevención & control , Ticarcilina/uso terapéutico , Adulto , Anciano , Antibacterianos/economía , Antineoplásicos/uso terapéutico , Aztreonam/economía , Cefepima , Cefalosporinas/economía , Ácido Clavulánico/economía , Costos y Análisis de Costo , Quimioterapia Combinada/economía , Quimioterapia Combinada/uso terapéutico , Femenino , Fiebre , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/radioterapia , Neutropenia , Infecciones Oportunistas/inmunología , Trasplante de Células Madre de Sangre Periférica , Ticarcilina/economíaRESUMEN
The incidence and clinical relevance of tumor cells contaminating the stem cell products of patients with advanced breast cancer treated with high-dose chemotherapy is uncertain because prior studies used small sample sizes and lacked standardization of the immunocytochemistry (ICC) detection method used. We evaluated blood stem cell and bone marrow samples obtained from 535 women with metastatic breast cancer who received high-dose chemotherapy and unmanipulated mobilized blood stem cell support. Of the patients tested, 20.6% and 26.3% had blood stem cell and bone marrow contamination, respectively. Blood stem cell contamination was significantly more frequent in patients with marrow involvement than in patients without marrow involvement (35% versus 18.4%, respectively; P = .009). In fact, according to multivariate analysis results, marrow involvement was the only significant predictor for blood stem cell product contamination. Patients without marrow involvement who had fewer apheresis procedures were also observed to have a significantly lower incidence rate of blood stem cell contamination than patients who had more procedures (P < or = .008), and patients who received combined chemotherapy and cytokine mobilization therapy had less contamination than patients who received cytokine alone (P = .0001). Combined mobilization therapy appears to be associated with a lower incidence of contamination as a result of fewer apheresis procedures rather than through an antitumor effect of chemotherapy (P < or = .001). Patients with ICC-negative blood stem cell products had significantly longer progression-free survival (PFS) and overall survival (OS) than did patients with ICC-positive blood stem cell products (median PFS, 401 versus 291 days, respectively, P = .007; median OS, 1060 versus 697 days, P = .009) . However, multivariate analysis did not reveal any significant independent predictors of survival outcomes. Thus, further study is needed to determine if contaminating tumor cells in the stem cell products of breast cancer patients ever directly impact survival outcomes or are only indicative of residual in vivo disease in high-dose chemotherapy recipients.
Asunto(s)
Neoplasias de la Mama/patología , Neoplasias de la Mama/terapia , Células Neoplásicas Circulantes/patología , Trasplante de Células Madre de Sangre Periférica/normas , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Médula Ósea/patología , Neoplasias de la Médula Ósea/secundario , Neoplasias de la Mama/mortalidad , Femenino , Movilización de Célula Madre Hematopoyética/efectos adversos , Humanos , Persona de Mediana Edad , Trasplante de Células Madre de Sangre Periférica/mortalidad , Factores de Riesgo , Análisis de Supervivencia , Trasplante Autólogo/mortalidad , Trasplante Autólogo/normas , Resultado del TratamientoRESUMEN
Although numerous reports indicate that patients receiving autotransplants for lymphoma are at increased risk for myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), the separate contributions of pretransplantation- and transplantation-related therapy are not well characterized. We conducted a case-control study of 56 patients with MDS/AML and 168 matched controls within a cohort of 2 739 patients receiving autotransplants for Hodgkin disease or non-Hodgkin lymphoma at 12 institutions (1989-1995). Detailed abstraction of medical records was undertaken to determine all pre- and posttransplantation therapy, and transplantation-related procedures. In multivariate analyses, risks of MDS/AML significantly increased with the intensity of pretransplantation chemotherapy with mechlorethamine (relative risks [RRs] = 2.0 and 4.3 for cumulative doses < 50 mg/m2 and > or = 50 mg/m,2 respectively; trend over dose categories, P =.04) or chlorambucil (RRs = 3.8 and 8.4 for duration < 10 months or > or = 10 months, respectively; trend, P =.009), compared with cyclophosphamide-based therapy. Transplantation-conditioning regimens including total-body irradiation (TBI) at doses 12 Gy or less did not appear to elevate leukemia risk (RR = 1.3; P =.48) compared with non-TBI regimens; however, a statistically significant increased risk was found for TBI doses of 13.2 Gy (RR = 4.6; P =.03). Peripheral blood stem cells were associated with a nonsignificant increased risk of MDS/AML (RR = 1.8; P =.12) compared with bone marrow grafts. Our data show that type and intensity of pretransplantation chemotherapy with alkylating agents are important risk factors of MDS/AML following autotransplantation. Transplantation-related factors may also modulate this risk; however, the apparent contribution of high-dose TBI requires confirmation.
Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Leucemia Mieloide/epidemiología , Linfoma/terapia , Síndromes Mielodisplásicos/epidemiología , Neoplasias Primarias Secundarias/epidemiología , Trasplante de Células Madre de Sangre Periférica/efectos adversos , Enfermedad Aguda , Adolescente , Adulto , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Estudios de Casos y Controles , Niño , Clorambucilo/administración & dosificación , Clorambucilo/efectos adversos , Estudios de Cohortes , Ciclofosfamida/administración & dosificación , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Leucemia Mieloide/etiología , Leucemia Inducida por Radiación/epidemiología , Leucemia Inducida por Radiación/etiología , Masculino , Mecloretamina/administración & dosificación , Mecloretamina/efectos adversos , Persona de Mediana Edad , Análisis Multivariante , Síndromes Mielodisplásicos/etiología , Neoplasias Primarias Secundarias/etiología , Prednisona/administración & dosificación , Procarbazina/administración & dosificación , Riesgo , Acondicionamiento Pretrasplante/efectos adversos , Trasplante Autólogo , Vincristina/administración & dosificación , Irradiación Corporal Total/efectos adversosRESUMEN
We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in remission at the time of transplantation (P <.001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age >or=40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.